論文

査読有り
2017年5月

Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer

ANTICANCER RESEARCH
  • Kyoko Inadomi
  • ,
  • Hitoshi Kusaba
  • ,
  • Yuzo Matsushita
  • ,
  • Risa Tanaka
  • ,
  • Kenji Mitsugi
  • ,
  • Kohei Arimizu
  • ,
  • Gen Hirano
  • ,
  • Akitaka Makiyama
  • ,
  • Hirofumi Ohmura
  • ,
  • Keita Uchino
  • ,
  • Fumiyasu Hanamura
  • ,
  • Yoshihiro Shibata
  • ,
  • Miyuki Kuwayama
  • ,
  • Taito Esaki
  • ,
  • Kotoe Takayoshi
  • ,
  • Shuji Arita
  • ,
  • Hiroshi Ariyama
  • ,
  • Koichi Akashi
  • ,
  • Eishi Baba

37
5
開始ページ
2663
終了ページ
2671
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.21873/anticanres.11614
出版者・発行元
INT INST ANTICANCER RESEARCH

Background: Significant efficacy of oxaliplatin-based chemotherapy has been demonstrated for advanced gastric cancer (AGC). However, the appropriate dose of oxaliplatin, and the efficacy and toxicity of administration of oxaliplatin subsequent to cisplatin therapy still remain unclear. Patients and Methods: In total, 55 patients with AGC that were scheduled to receive oxaliplatin-based chemotherapy were prospectively examined. Results: The median age was 67 years and oxaliplatin was administered to 39 (71%) patients as first-line and in 16 (29%) patients as second-line therapy. An initial dose of 130 or 100 mg/m(2) of oxaliplatin was administered to 11 and 36 patients, respectively. The overall response rates (ORR) and median progression free survival (mPFS) were 86 and 33%, and 7.2 and 7.8 months, respectively. Compared to 100 mg/m(2), the relative dose intensity was significantly lower and severe toxicity tended to increase with oxaliplatin at 130 mg/m(2). A total of 10 patients (18%) had a prior cisplatin-based therapy. The ORR of the patients pretreated with cisplatin was 14% and the mPFS was 6.1 months. Conclusion: An initial oxaliplatin dose of 130 mg/m(2) resulted in a good response, but tended to increase the risk of toxicity. Subsequent oxaliplatin-based therapy after cisplatin exhibited modest efficacy, especially in cases with cisplatin intolerance.

Web of Science ® 被引用回数 : 12

リンク情報
DOI
https://doi.org/10.21873/anticanres.11614
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28476842
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000402173300064&DestApp=WOS_CPL
ID情報
  • DOI : 10.21873/anticanres.11614
  • ISSN : 0250-7005
  • eISSN : 1791-7530
  • PubMed ID : 28476842
  • Web of Science ID : WOS:000402173300064

エクスポート
BibTeX RIS